Concurrent Review in Rehab: How Insurers Approve More Days
Table of Contents
Most families assume that once an insurance plan approves residential rehab, the stay is approved. In practice, that first approval usually covers a limited number of days, and the rest of the stay is decided in a series of conversations between the treatment team and the insurer while the person is already in care. This process is called concurrent review (or utilization review), and understanding it early prevents the most stressful surprise in residential treatment: a phone call saying coverage ends on Friday.
This guide explains how concurrent review works for a residential substance use stay in California, what drives the outcome, and what you can do on the first day of admission to stay ahead of it.
What concurrent review actually is
When someone is admitted to residential treatment in Los Angeles using insurance, the admissions team requests an initial authorization. The insurer approves a set number of days and assigns a date for the next review. Before that date, a clinician from the treatment program speaks with or submits records to a utilization reviewer at the health plan. The reviewer decides whether the person still meets medical necessity criteria for that level of care. If yes, more days are authorized and a new review date is set. If not, the plan approves a lower level of care, such as partial hospitalization or intensive outpatient, or issues a denial for further residential days.
The number of days approved at each step varies by plan and by clinical picture. Some plans approve a handful of days at a time; others approve longer blocks. There is no universal schedule, which is why the most useful thing a family can know is not a general rule but the specific dates on the specific authorization.
The standard reviewers use
For substance use treatment, most reviewers frame their questions around the ASAM Criteria, the American Society of Addiction Medicine’s framework for matching a person to a level of care across six dimensions: withdrawal risk, physical health, emotional and behavioral conditions, readiness to change, relapse risk, and recovery environment. A residential stay continues to be approved when the clinical record shows that one or more of those dimensions still requires a 24-hour structured setting.
In California, health plans regulated by the Department of Managed Health Care must resolve a standard grievance within 30 days and an urgent grievance within three days, and since January 1, 2021, state law (SB 855) has required plans to base substance use medical necessity decisions on criteria developed by nonprofit clinical associations such as ASAM rather than on their own proprietary guidelines. Families who know those three facts can tell quickly whether a coverage decision is being made on the right standard and on the right timeline.
Some PPO policies in California are regulated by the Department of Insurance rather than the Department of Managed Health Care, and self-funded employer plans fall under federal rules instead. The back of the insurance card, or the plan documents, will usually say which applies. Our PPO insurance rehab page covers how out-of-network benefits typically interact with residential care.
Why a review comes back with fewer days than expected
In our experience at a small six-bed residence, short authorizations are rarely about whether someone “deserves” more treatment. They usually trace back to what the record does or does not show on the day of the call:
- Documentation lag: progress notes that describe stability without recording the specific risks that remain give the reviewer nothing to approve against.
- Withdrawal phase ending: once acute withdrawal resolves, some reviewers treat dimension one as satisfied and look for justification in the other five dimensions instead.
- Unrecorded co-occurring symptoms: when depression, anxiety or trauma symptoms are affecting someone’s ability to stay engaged in substance use treatment but are not documented as part of the dual diagnosis plan, the reviewer cannot weigh them.
- Recovery environment not described: a home where others drink or use, or no safe place to discharge to, is a recognised ASAM factor, but only if someone has written it down.
- Missed peer-to-peer window: many plans offer a call between the program’s physician and the plan’s physician after an adverse decision, but the window to request it can be short.
None of these mean the treatment team is doing something wrong. They reflect how the review process reads a chart. For people in dual diagnosis treatment, where a co-occurring condition like PTSD or bipolar disorder affects relapse risk, careful documentation of how the two conditions interact is often what supports continued residential care.
What to do on admission day
Ask the admissions or utilization review coordinator for four pieces of information, and write them down in one place, such as a note on your phone:
- The authorization or reference number for the current approval.
- How many residential days were approved, and the exact last covered date.
- The date and time of the next scheduled review.
- Who at the program handles reviews, and the best way to reach them.
Then ask one more question: “If the next review comes back short, what is the plan, and how much notice will we get?” A good program will have an answer, whether that is requesting a peer-to-peer review, filing an expedited appeal, stepping down to a lower level of care, or discussing private-pay options for additional days. Knowing the answer before the review is very different from hearing it after.
If you are still choosing a program and want to understand how this works before admission, you can call our team at (855) 778-8668 and ask how utilization review is handled during a stay.
If coverage is reduced mid-stay
An adverse decision is not always the end of the conversation. The usual sequence is a peer-to-peer call first, then an internal appeal or grievance with the plan, marked urgent if a delay could seriously jeopardise health. In California, if the plan upholds its decision or does not respond in time, people in plans regulated by the Department of Managed Health Care can generally request an Independent Medical Review through that department. Federal parity law, the Mental Health Parity and Addiction Equity Act of 2008, also requires that limits on substance use treatment be no more restrictive than limits on comparable medical and surgical care.
While a decision is pending, safety comes first. Leaving residential care abruptly during or shortly after withdrawal can be dangerous. Alcohol and benzodiazepine withdrawal can cause seizures and must be managed under medical supervision; if a person still has withdrawal symptoms, discharge planning should include continued medically supervised detox or a supervised step-down, never a sudden stop at home. People leaving treatment after a period of abstinence from opioids also have lower tolerance, which raises overdose risk; the National Institute on Drug Abuse explains why reduced tolerance matters and why naloxone should be on hand.
Why length of stay matters
Research summarised by NIDA in its Principles of Drug Addiction Treatment emphasises that remaining in treatment for an adequate period is important, and that the right duration depends on the individual. Concurrent review is the mechanism that, in practice, decides how long insurance will pay for that period. That is why it deserves the same attention as choosing the program itself.
It also helps to remember that a step-down is not a failure. Moving from residential to partial hospitalization or intensive outpatient care can be the clinically right next step. The goal of tracking reviews is not to stay in residential care as long as possible; it is to make sure every transition is planned, supported and safe rather than triggered by a date nobody saw coming.
Questions to bring to the next review
If you are a family member with permission to receive updates (under federal confidentiality rules, the person in treatment generally needs to consent in writing), these are fair questions to ask the treatment team before each review:
- Which ASAM dimensions are you documenting as still needing residential care?
- Is the recovery environment at home part of the record?
- If days are reduced, will the program request a peer-to-peer review the same day?
- What does the discharge or step-down plan look like if coverage ends?
For help finding treatment options or understanding coverage, the SAMHSA National Helpline is free, confidential and available 24 hours a day at 1-800-662-4357. To talk with Annandale about residential substance use and co-occurring treatment, insurance verification, or how reviews are handled during a stay, call (855) 778-8668.
If you or someone you love is in crisis or thinking about suicide, call or text 988 to reach the 988 Suicide & Crisis Lifeline. In a medical emergency, call 911.
This article is for educational purposes only and is not medical, legal or insurance advice. Coverage rules differ between plans, and timelines can change. Check your own plan documents, and speak with a qualified clinician about any treatment or medication decision.







